Dr Yannic Bartsch's TWINCORE junior research group "Antiviral Antibody Omics" is being funded as a Helmholtz Young Investigator Group (HYIG). Over the next five years, the immunologist will receive a total of 1.5...
The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available for many viral...
Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. What causes these differences is not fully understood. It is already known that an...
In the ImageTox project, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the CISPA Helmholtz Center for Information Security are pooling their expertise in the fields of drug discovery and...
Systematically attenuating DNA targeting activity can achieve CRISPR-driven editing in bacteria, greatly boosting colony counts and even increasing the frequency of precise genome editing. This was shown in a study of...
Before new drugs can be tested in animal experiments and later in clinical trials, they must undergo a large number of laboratory tests. This involves the use of so-called cell lines, i.e. human or animal cells of a...
The European Research Council (ERC) grants are among the most prestigious awards in the scientific community. Prof Anna Hirsch from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now succeeded...
The pathogen Pseudomonas aeruginosa is the cause of a large number of serious infections and places a particular burden on immunocompromised patients. The increasing spread of antimicrobial resistance makes it even more...
